Radiotherapy of multiple extracranial metastases simultaneously according to a common radiation plan vs sequentially according to a radiation plan per metastasis

Switzerland (ICTRP)

ICTRP Trial ID
NCT06230666 (ICTRP)

Official title (approved by ethics committee)
SINGLE-ISOCENTER SBRT VS MULTIPLE-ISOCENTER SBRT FOR MULTIPLE EXTRACRANIAL METASTASES: a randomized controlled non-inferiority clinical trial (BASEC)

Academic title
Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases: a Randomized Controlled Non-inferiority Clinical Trial (ICTRP)

Public title
Single-isocenter SBRT vs. Multiple-isocenter SBRT for Multiple Extracranial Metastases (ICTRP)

Disease under investigation

Metastatic Cancer

(ICTRP)

Intervention under investigation

Radiation: SBRT

(ICTRP)

Type of trial
Interventional (ICTRP)

Trial design

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

(ICTRP)

Inclusion/Exclusion criteria

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

• Written informed consent according to Swiss law and ICH/GCP regulations signed and dated by the participant and the investigator before any trial specific procedures (Informed Consent Form);
• Distant extracranial metastases (lung, mediastinal/cervical lymph node, liver, bone including spinal/paraspinal and abdominal/pelvic) from histologically confirmed cancer;
• Distant metastases confirmed by imaging:
• CT is required in all cases;
• MRI is required for spinal and recommended for liver metastases;
• PET/CT is recommended for tumors showing high uptake of 18F-FDG, 11Ccholine, 68Ga- or 18F-PSMA;
• At least 2 distant metastases that are amendable to treat with a single isocenter approach according to the judgment of the treating clinician;
• Patients who are willing and able to comply with scheduled visits, treatment, and other trial procedures.

Exclusion Criteria:

• Prior radiotherapy for distant metastases if overlapping previous and current treatment plans leads to excessive dose to OARs;
• Distant metastases with extension into the gastrointestinal tract, skin;
• Large inter-lesion distance and location of distant metastases in different organs with different motion patterns;
• Women who are pregnant or breast feeding;
• Intention to become pregnant during the course of the trial;
• Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases;
• Known or suspected non-compliance, drug or alcohol abuse;
• Inability to follow the procedures of the trial, e.g. due to language problems of the participant;
• Enrolment of the investigator, his/her family members, employees and other dependent persons.

Female participants who underwent hysterectomy and/or bilateral oophorectomy or
postmenopausal for longer than 2 years are not considered as being of child bearing
potential.

(ICTRP)

not available

Primary and secondary end points

Freedom from local disease progression at the site of treated metastases

(ICTRP)

Acute adverse events (AEs);Late adverse events (AEs);Overall survival;Progression-free survival;Overall treatment time

(ICTRP)

Registration date
not available

Incorporation of the first participant
not available

Secondary sponsors
not available

Additional contacts
Indira Madani, MD, PhD, indira.madani@usz.ch, +41 44 255 37 68 (ICTRP)

Secondary trial IDs
2023-01904 (ICTRP)

Results-Individual Participant Data (IPD)
not available

Further information on the trial
https://clinicaltrials.gov/ct2/show/NCT06230666 (ICTRP)